S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
NASDAQ:CYTK

Cytokinetics Stock Forecast, Price & News

$30.30
-0.51 (-1.66%)
(As of 01/21/2022 04:00 PM ET)
Add
Compare
Today's Range
$29.93
$31.54
50-Day Range
$30.30
$46.38
52-Week Range
$17.72
$47.90
Volume
1.55 million shs
Average Volume
1.21 million shs
Market Capitalization
$2.54 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.23
30 days | 90 days | 365 days | Advanced Chart
Receive CYTK News and Ratings via Email

Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter.


Cytokinetics logo

About Cytokinetics

Cytokinetics, Inc. operates as a biopharmaceutical company. The firm focuses on the discovery and development of muscle activators as potential treatment for debilitating diseases. It conducts a Phase 2 clinical trials program for tirasemtiv, including a Phase 2b clinical trial in patients with ALS, known as BENEFIT-ALS (Blinded Evaluation of Neuromuscular Effects and Functional Improvement with Tirasemtiv in ALS). The company was founded on August 5, 1997 and is headquartered in South San Francisco, CA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CYTK
Employees
184
Year Founded
1997

Sales & Book Value

Annual Sales
$55.83 million
Book Value
$1.60 per share

Profitability

Net Income
$-127.29 million
Net Margins
-1,061.13%
Pretax Margin
-1,061.13%

Debt

Price-To-Earnings

Miscellaneous

Free Float
79,102,000
Market Cap
$2.54 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/03/2021
Today
1/23/2022
Next Earnings (Estimated)
2/24/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

2.07 out of 5 stars

Medical Sector

548th out of 1,418 stocks

Pharmaceutical Preparations Industry

257th out of 684 stocks

Analyst Opinion: 4.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -












Cytokinetics (NASDAQ:CYTK) Frequently Asked Questions

Is Cytokinetics a buy right now?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Cytokinetics stock.
View analyst ratings for Cytokinetics
or view top-rated stocks.

How has Cytokinetics' stock price been impacted by Coronavirus?

Cytokinetics' stock was trading at $12.03 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CYTK stock has increased by 151.9% and is now trading at $30.30.
View which stocks have been most impacted by COVID-19
.

When is Cytokinetics' next earnings date?

Cytokinetics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Cytokinetics
.

How were Cytokinetics' earnings last quarter?

Cytokinetics, Incorporated (NASDAQ:CYTK) released its earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.75) by $0.20. The biopharmaceutical company earned $5.44 million during the quarter, compared to the consensus estimate of $5.46 million. Cytokinetics had a negative net margin of 1,061.13% and a negative trailing twelve-month return on equity of 204.75%. During the same period last year, the company posted ($0.05) earnings per share.
View Cytokinetics' earnings history
.

What price target have analysts set for CYTK?

13 brokers have issued twelve-month price objectives for Cytokinetics' stock. Their forecasts range from $40.00 to $75.00. On average, they expect Cytokinetics' share price to reach $53.38 in the next year. This suggests a possible upside of 76.2% from the stock's current price.
View analysts' price targets for Cytokinetics
or view top-rated stocks among Wall Street analysts.

Who are Cytokinetics' key executives?

Cytokinetics' management team includes the following people:

What is Robert I. Blum's approval rating as Cytokinetics' CEO?

16 employees have rated Cytokinetics CEO Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among Cytokinetics' employees.

What other stocks do shareholders of Cytokinetics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD).

What is Cytokinetics' stock symbol?

Cytokinetics trades on the NASDAQ under the ticker symbol "CYTK."

Who are Cytokinetics' major shareholders?

Cytokinetics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Frontier Capital Management Co. LLC (0.79%), Asymmetry Capital Management L.P. (0.27%), Russell Investments Group Ltd. (0.24%), State of Alaska Department of Revenue (0.07%), Louisiana State Employees Retirement System (0.05%) and Crossmark Global Holdings Inc. (0.01%). Company insiders that own Cytokinetics stock include B Lynne Parshall, Bvf Partners L P/Il, Ching Jaw, David Cragg, Edward M Md Kaye, Fady Ibraham Malik, John T Henderson, John T Henderson, L Patrick Gage, Mark A Schlossberg, Robert I Blum, Robert I Blum, Sandford D Smith, Sandford D Smith, Santo J Costa and Wendall Wierenga.
View institutional ownership trends for Cytokinetics
.

Which major investors are selling Cytokinetics stock?

CYTK stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Asymmetry Capital Management L.P., Crossmark Global Holdings Inc., Cutler Group LP, and State of Alaska Department of Revenue. Company insiders that have sold Cytokinetics company stock in the last year include B Lynne Parshall, Ching Jaw, David Cragg, Edward M Md Kaye, Fady Ibraham Malik, John T Henderson, L Patrick Gage, Mark A Schlossberg, Robert I Blum, Sandford D Smith, and Wendall Wierenga.
View insider buying and selling activity for Cytokinetics
or view top insider-selling stocks.

Which major investors are buying Cytokinetics stock?

CYTK stock was purchased by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., and Louisiana State Employees Retirement System.
View insider buying and selling activity for Cytokinetics
or or view top insider-buying stocks.

How do I buy shares of Cytokinetics?

Shares of CYTK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cytokinetics' stock price today?

One share of CYTK stock can currently be purchased for approximately $30.30.

How much money does Cytokinetics make?

Cytokinetics has a market capitalization of $2.54 billion and generates $55.83 million in revenue each year. The biopharmaceutical company earns $-127.29 million in net income (profit) each year or ($3.09) on an earnings per share basis.

How many employees does Cytokinetics have?

Cytokinetics employs 184 workers across the globe.

When was Cytokinetics founded?

Cytokinetics was founded in 1997.

What is Cytokinetics' official website?

The official website for Cytokinetics is www.cytokinetics.com.

Where are Cytokinetics' headquarters?

Cytokinetics is headquartered at 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Cytokinetics?

Cytokinetics' mailing address is 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at (650) 624-3000, via email at [email protected], or via fax at 650-624-3010.


This page was last updated on 1/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.